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ICUAbstract Community-acquired pneumonia (CAP) is a serious and widespread infection due to its
high incidence, morbidity, mortality and increased healthcare costs. This study aimed at investigat-
ing antibiotic combination regimen containing ﬂuoroquinolone (Group A) and antibiotic combina-
tion regimen not containing ﬂuoroquinolone (Group B) in terms of effectiveness parameters and
direct medical costs associated with treatment of CAP patients admitted to Intensive Care Unit
(ICU). This study was designed as retrospective and prospective observational studies including
CAP patients admitted to the Respiratory ICU. The patients’ ﬁles were collected and the effective-
ness parameters of outcomes were compared on admission and on discharge. Effectiveness and
costs analyses between antibiotic regimens either containing or not containing ﬂuoroquinolone were
performed. A total of 16 patients were enrolled in our retrospective study; (Group A) included 7
patients, while (Group B) included 9 patients. The prospective study included 30 patients; (Group
A) included 13 patients and (Group B) included 17 patients. There was non-signiﬁcant difference in
the number of days in ICU between the two groups with a trend to shorter length of stay in ICU in
(Group B) compared to (Group A) in both retrospective and prospective studies. Cost analysis
showed that there was non-signiﬁcant difference with a trend to lower direct medical costs in
(Group B) which resulted in cost savings of (L.E) 1277 and (L.E) 816 for retrospective study and
prospective study respectively. In conclusion, regimens containing or not containing ﬂuoroquino-
lone did not show a signiﬁcant increase in either effectiveness or costs of CAP treatment in the ICU.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
Community-acquired pneumonia (CAP) is a serious and wide-
spread infection due to its high incidence, morbidity, mortality
and increased healthcare costs. These factors make CAP asso-
ciated with great implications for healthcare systems around
136 W.A. Harwan et al.the world especially in patients who are admitted to the inten-
sive care unit (ICU). Mortality rates in ICU patients reached
more than 50%.1 CAP is the ﬁrst common cause of death
due to infectious diseases and generally the sixth leading cause
of death in the United States.1,2
Due to the fact that causative pathogens responsible for
CAP are not mostly identiﬁable by diagnostic tests, the empir-
ical antibiotic treatment is applied in most cases and should
target the most common typical pathogens of CAP such
as (Streptococcus pneumoniae and Haemophilus inﬂuenzae)
and atypical pathogens such as (Chlamydia pneumoniae,
Mycoplasma pneumonia, and Legionella pneumophila) which
account for 33% of CAP infection and are not sensitive
in vitro to b-lactam.1,3
Recommendations for two common empirical approaches
were identiﬁed: (1) b-lactam/b-lactamase inhibitor or (second-
or third-generation) cephalosporin plus a macrolide; and (2)
the oral respiratory ﬂuoroquinolones.4–6 Fluoroquinolones
are an important option in the treatment of CAP due to the
advantages of a wide spectrum property, high oral bioavail-
ability, low resistance potential, efﬁcacy and safety.5,7 CAP
patients who are treated with ﬂuoroquinolones exhibited
increased clinical response, faster resolution, greater improve-
ment of signs and symptoms and shorter hospital stay com-
pared to combination or nonstandardized therapies.8
Pharmacoeconomics is the description and analysis of the
costs of drug therapy to health care systems and society. It
identiﬁes, measures, and compares the costs and consequences
of pharmaceutical products and services. It measures if the
added beneﬁt of one intervention is worth the added cost of
that intervention. Basic components of pharmacoeconomics
are the drug product or service, costs and outcomes. If out-
comes and costs are measured; but clinical outcomes are found
to be equivalent (or assumed to be the same); and the costs of
the alternatives are compared, then the study is cost-minimiza-
tion analysis (CMA). Generally if costs are measured without
regard for outcomes, it is a cost analysis (or partial economic
analysis).9
Up-to-date there are no previous studies exploring antibi-
otic use and the pharmacoeconomics of CAP in ICU in Egypt.
The objective of this study is to compare antibiotic combina-
tion regimen containing ﬂuoroquinolone and antibiotic combi-
nation regimen not containing ﬂuoroquinolone to investigate
effectiveness parameters of patient outcomes to determine
the efﬁcacy or the equivalency of the two regimens and to eval-
uate direct medical costs associated with treatment of CAP
patients in the ICU via cost analysis.
2. Subjects and methods
2.1. Study design
This study was designed as a prospective observational study.
However, to ensure the possibility of conducting the study in
the current hospital, we performed a similar study retrospec-
tively using the patient records admitted to the ICU in the per-
iod from 2010 to 2011. The prospective study was conducted in
the period from 2011 to 2012. All patients were admitted to the
Respiratory Intensive Care Unit (RICU), Ain Shams Univer-
sity Hospital; Cairo; Egypt, for severe community-acquired
pneumonia (CAP) and required initial intravenous therapy.Patients were divided into two groups; (Group A taking anti-
biotic regimen containing ﬂuoroquinolone) and (Group B tak-
ing antibiotic regimen not containing ﬂuoroquinolone). This
study was approved by the Research Ethics Committee of Fac-
ulty of Pharmacy; Cairo University (CL 207). The attending
physician was responsible for prescribing the antibiotic combi-
nation regimen in ICU and no intervention was applied
because the observational nature of the study.
Inclusion criteria were: (1) adult patients 20–65 years old;
and (2) patients diagnosed with community-acquired pneumo-
nia admitted to the ICU, meeting at least one major criterion
or three minor criteria of the Infectious Disease Society of
America/American Thoracic Society guidelines.10
Patients were excluded from the study if they had one of the
following exclusion criteria: (1) children, pregnant women and
elderly patients over 65 years old, (2) aspiration or hospital-
acquired pneumonia, (3) discharge from hospital within the
previous 14 days, (4) transferred from another hospital (unless
transferred within 4 h of presentation at the original hospital),
(5) immunosuppressed (HIV positive or immunosuppressant
therapy or concurrent chemotherapy), (6) chronic chest disease;
suspected or conﬁrmed tuberculosis; aspiration or obstructive
pneumonia; cystic ﬁbrosis or bronchiectasis, (7) concomitant
infections (e.g. sinusitis, urinary tract infections), (8) acute burn
injury, (9) malignancy, and (10) major gastrointestinal bleeding
within three months of the current hospitalization.
2.2. Data collection and assessment
Data were collected from the patient’s ﬁles for the retrospec-
tive study and all prospective patients were assessed on hospi-
tal admission, during follow-up and on hospital discharge. The
following parameters were monitored and evaluated for each
patient: (1) demographical data (age, gender, date of admis-
sion, date of discharge from ICU); (2) clinical symptoms and
features suggesting CAP on admission (cough, fever, chest
pain, dyspnea, mental confusion and aspiration); (3) clinical
signs (body temperature, blood pressure, respiratory rate and
heart rate); (4) comorbidities; (5) diagnostic evaluation by
chest X-ray at least on admission and at day 8; (6) routine lab-
oratory screen including Complete Blood Count (CBC), coag-
ulation proﬁle, Blood Urea Nitrogen (BUN), creatinine, liver
enzymes including Alanine Aminotransferase (ALT) and
Aspartate Aminotransferase (AST) and serum bilirubin; (7)
arterial Blood Gases (ABG) (pH, Pao2, Pco2) at least once
daily to detect Pao2:Fio2; (8) culture and sensitivity of sputum,
blood, urine or bronchoalveolar lavage to diagnose etiology of
pneumonia and microbiological ﬁndings; (9) prescribed antibi-
otic regimen (empirical and after culture therapy); and (10)
length of stay in ICU and death.
2.3. Antibiotic treatment regimen evaluation
The prescribed antibiotic regimen was recorded for each
patient during stay in the ICU. The empirical antibiotic ther-
apy was prescribed during the ﬁrst 24 h of an admission to
the ICU without waiting of an etiologic diagnosis due to the
severity of illness. We compared prescribed antibiotic combi-
nation regimens to the American Thoracic Society (ATS)
and the Infectious Diseases Society of America (IDSA) antibi-
otic guidelines for CAP in ICU.
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score (SOFA score) on admission and on discharge
SOFA scores were evaluated and calculated on admission and
on discharge for each patient with CAP admitted to the ICU to
predict their outcome.11 The total SOFA score was calculated
as the sum of SOFA scores on admission and on discharge
during ICU stay for each patient.
2.5. Effectiveness parameters of patient outcomes
The following effectiveness parameters of outcomes were cal-
culated for each patient during stay in the ICU: (1) number
of days in the ICU; (2) number of days on mechanical ventila-
tor; and (3) Sequential Organ Failure Assessment score (SOFA
score) on admission and on discharge. The following effective-
ness parameters of outcomes were calculated for each patient
during stay in the ICU: (1) number of days in the ICU; (2)
number of days on mechanical ventilator; and (3) Sequential
Organ Failure Assessment score (SOFA score) on admission
and on discharge.
2.6. Costs calculation
Different costs were calculated during the stay of patients in
the ICU as follow:
1. Costs of antibiotics = [cost of antibiotic unit ·
(frequency \ No. of days)].
2. Costs of other medications = [cost of medication ·
(frequency \ No. of days)].
3. Costs of laboratory tests = [cost of Lab tests ·
(frequency \ No. of days)].
4. Costs of other diagnostic tests = [cost of other diagnostic
tests · (frequency \ No. of days)].
5. Total ICU costs of antibiotics, other medications, labora-
tory tests & other diagnostic tests per hospital stay = (cost
of antibiotics + cost of other medications + cost of Lab
tests + costs of other diagnostic tests).
\ All costs are in Egyptian Pound.
\ Estimation of all direct medical costs was similar to that
estimated by Dresser et al.12 and Samsa et al.13
2.7. Costs analysis
After comparison of effectiveness parameters between the two
groups in the ICU, the choice of appropriate pharmacoeco-
nomic analysis was dependent on whether the two regimens
compared in the two groups were equivalent or not. Data
available for the primary cost analysis in this study included
all direct medical costs used in the treatment of CAP patients
in the ICU in addition to number of days in ICU. The primary
outcome parameter in this cost analysis is the estimated direct
medical costs per patient in the two comparable groups.
2.8. Statistical analysis
Statistical analysis was performed by statistical software
(GraphPad Prism version 6.02; 1992–2013 GraphPad software,Inc.). Continuous data were presented as mean ± SD or med-
ian or number (%). Mann–Whitney U test was performed due
to the small sample size in the two groups. Categorical variables
were compared using Fisher’s exact test. Level of signiﬁcance of
5% (p-value < 0.05) was used and the exact p-values were
recorded.3. Results
3.1. Population characteristics
3.1.1. Retrospective results
A total of 16 patients were enrolled in our retrospective study
[11 males (68.75%) and 5 females (31.25%)]. Group A
included 7 patients [5 males (71.4%) and 2 females (28.6%)],
while Group B included 9 patients [6 males (66.7%) and 3
females (33.3%)]. The patients were admitted to the Ain
Shams University hospital during the period between 2010
and 2011. The mean age ± SD was 47.71 ± 11.72 years in
Group A compared to the mean age ± SD of 50.90 ±
10.87 years in (Group B). The median age of 49 years of
Group A was compared statistically with the median age of
55 years of Group B. There was non-signiﬁcant difference at
(p-value < 0.05) in the median age between the two groups
(p-value = 0.5892). Respiratory failure grade I was the most
frequent comorbid condition in the two groups, with higher
percentage in Group A, (71.4%) than in Group B,
(66.7%).The epidemiological characteristics of the two groups
are shown in (Table 1). No signiﬁcant difference was found in
any of the categories using the Fisher’s exact test.
3.1.2. Prospective results
All patients admitted to the ICU during the study period due
to CAP were screened for the study. Only 30 patients were eli-
gible [17 males (56.7%) and 13 females (43.3%)]. Group A
included 13 patients [9 males (69.2%) and 4 females (30.8%)]
and Group B included 17 patients [8 males (47%) and 9
females (53%)]. The patients were admitted to the Ain Shams
University hospital during the period between 2011 and 2012.
The mean age ± SD was 54.61 ± 10.40 years in Group A
compared to the mean age ± SD of 44.52 ± 15.90 years in
Group B. The median age of 58 years in Group A was com-
pared statistically with the median age of 51 years in Group
B. Non-signiﬁcant difference was obtained comparing the
median age between the two groups (p-value = 0.0908). The
most frequent comorbid illness in Group A was hypertension
with a percentage of (53.8%) compared to Group B with pleu-
ral effusion (35.3%) as the highest comorbid illness. The epide-
miological characteristics of the two groups are shown in
(Table 2). Signiﬁcantly more patients in the levoﬂoxacin group
were hypertensive than in the non-levoﬂoxacin group. All
other variables were not signiﬁcantly different.
3.2. Microbiological diagnosis and causes of pneumonia
3.2.1. Retrospective results
Positive culture results (positive isolated pathogens) were
reported in 4 (57.14%) of 7 patients in Group A. Klebsiella
pneumoniae was the most frequently isolated etiologic agent
(n= 4, 100%) in these 4 patients compared to Pseudomonas
Table 1 Epidemiological characteristics of retrospective patients with community-acquired pneumonia who have antibiotic
combination regimens containing and not containing ﬂuoroquinolone and admitted to the ICU.
Variable (Group A) (regimen containing
levoﬂoxacin) (n= 7)
(Group B) (regimen not containing
levoﬂoxacin) (n= 9)
P-value
Age, mean years ± SD (median) 47.71 ± 11.72 (49) 50.90 ± 10.87 (55) 0.5892
Male gender 5 (71.4%) 6 (66.7%)
Comorbidities
Hypertension 1 (14.3%) 3 (33.3%) 0.5846
Diabetes 2 (28.6%) 2 (22.2%) 1.0000
Respiratory failure grade I 5 (71.4%) 6 (66.7%) 1.0000
Respiratory failure grade II 2 (28.6%) 1 (11.1%) 0.5500
Arterial embolism 0 2 (22.2%) 0.4750
Pleural eﬀusion 0 1 (11.1%) 1.0000
Renal impairment 2 (28.6%) 2 (22.2%) 1.0000
Cardiac disease 1 (14.3%) 1 (11.1%) 1.0000
Subacute deep venous thrombosis (DVT) 1 (14.3%) 0 0.4375
Liver disease 1 (14.3%) 1 (11.1%) 1.0000
Rheumatoid arthritis 0 1 (11.1%) 1.0000
Note: Data are presented as mean ± SD or median or number (%) of patients, unless otherwise indicated.
Level of signiﬁcance at p-value < 0.05 (Mann–Whitney test).
Fisher’s exact test was done for comorbidities (data which presented as frequencies).
Table 2 Epidemiological characteristics of prospective patients with community-acquired pneumonia who have antibiotic
combination regimens containing and not containing ﬂuoroquinolone and admitted to the ICU.
Variable (Group A) (regimen containing
ﬂuoroquinolone) (n= 13)
(Group B) (regimen not containing
ﬂuoroquinolone) (n= 17)
P-value
Age, mean years ± SD (median) 54.61 ± 10.40 (58) 44.52 ± 15.90 (51) 0.0908
Male gender 9 males (69.2%) 8 males (47%)
Comorbidities
Hypertension 7 (53.8%) 2 (11.8%) 0.0196*
Diabetes 4 (30.8%) 2 (11.8%) 0.3598
Respiratory failure grade I 4 (30.8%) 5 (29.4%) 1.0000
Respiratory failure grade II 5 (38.5%) 1 (5.9%) 0.0606
Pulmonary embolism 0 3 (17.6%) 0.2379
Arterial embolism 2 (15.4%) 0 0.1793
Pleural eﬀusion 2 (15.4%) 6 (35.3%) 0.4069
Renal impairment 4 (30.8%) 2 (11.8%) 0.3598
Cardiac disease 4 (30.8%) 5 (29.4%) 1.0000
Liver disease 3 (23.1%) 2 (11.8%) 0.6278
Chronic calcular gallbladder stones 1 (7.7%) 0 0.4333
Prostate illness 1 (7.7%) 1 (5.9%) 1.0000
Neurological illness 0 1 (5.9%) 1.0000
Anemia 0 2 (11.8%) 0.4920
Note: Data are presented as mean ± SD or median or number (%) of patients, unless otherwise indicated.
Level of signiﬁcance at p-value < 0.05 (Mann–Whitney test).
Fisher’s exact test was done for comorbidities (data which presented as frequencies).
* Signiﬁcant difference.
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25%). The expectorated sputum culture was done in all 4
patients who resulted in positive culture. One negative result
by sputum culture was obtained in addition to three culture
results in three patients that were not documented.
In (Group B), positive culture results were reported in 5
(55.6%) of 9 patients. K. pneumoniae was the most frequently
isolated etiologic agent (n= 3, 60%) in these 5 patients and S.
pneumoniae (n= 2, 40%) was the second isolated etiologic
agent. The expectorated sputum culture was done in all 5patients who resulted in positive culture. One negative culture
result by sputum was obtained in addition to four culture
results in four patients that were not documented.
3.2.2. Prospective results
Positive culture results were reported in 8 patients (61.5%) of
13 patients in Group A. Gram-negative bacilli (E. coli) and S.
pneumoniae (n= 2, 25%) were the most frequently isolated eti-
ologic agents in these 8 patients. The expectorated sputum was
cultured in 6 (75%) of 8 patients who resulted in positive
Figure 1 The difference of medians of effectiveness parameters
between (Group A) and (Group B) retrospective patients. Non-
signiﬁcant difference at p< 0.05 (Mann–Whitney test).
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in addition to three culture results in three patients that were
not documented. Urine culture was made in 1 patient
(12.5%) of 8 patients. There was one negative result by mid-
stream urine.
Positive culture results were reported in 11 (64.7%) of 17
patients in Group B. Of 11 patients, three patients were asso-
ciated with two culture results and two isolated microorgan-
isms and one patient had two culture results with three
isolated microorganisms. S. pneumoniae (n= 5, 45.5%) was
isolated frequently in these 11 patients. In Group B, the etio-
logic diagnosis was made by expectorated sputum culture in
9 (81.8%) of 11 patients. Of 9 patients, two isolated microor-
ganisms were identiﬁed by sputum culture. Urine culture was
made in two patients (18.2%) and one of them had two iso-
lated microorganisms. Blood culture and bronchoalveolar
lavage culture were made in one (9.1%) of 11 patients. Two
negative results by sputum culture and one negative result by
bronchoalveolar lavage were reported and there were three
not documented microbiological cultures.
3.3. Antibiotic treatment regimen
The empirical choice of antibiotic combination regimen was
decided by the attending physician dependent on the clinical
experience and the availability of antibiotics in the hospital
because there was no antibiotic policy. These antibiotic regi-
mens were changed by the attending physician according to
the culture results of each patient.
3.3.1. Retrospective results
The most common antibiotic combination regimen used in
Group A was [broad-spectrum ﬂuoroquinolone (Levoﬂoxacin)
plus advanced generation macrolide (azithromycin) (n= 2)].
While in Group B, b-lactam third generation cephalosporin
(ceftriaxone) plus advanced generation macrolide (azithromy-
cin) (n= 4) was the most frequent combination regimen used
in (Group B).
3.3.2. Prospective results
The most common antibiotic combination regimen used in
Group A was broad-spectrum ﬂuoroquinolone (levoﬂoxacin)
plus advanced generation macrolide (azithromycin)
(n= 5).On the other hand, b-lactam third generation cephalo-
sporin (ceftriaxone) plus advanced generation macrolide
(azithromycin) (n= 4) was the most common combination
regimen used in (Group B).
In the present study, empirical antibiotic regimens used for
the treatment of hospitalized patients with CAP included
mostly ﬂuoroquinolones, macrolides and b-lactams; in accor-
dance with ICU guidelines regarding choices. On the other
hand, the antibiotic combination regimens used were mostly
in disagreement with ATS and IDSA guidelines.
In the retrospective study, the majority of cases in (Group
A) (5 out of 7 patients) did not follow the ATS/IDSA guide-
lines. Antibiotic monotherapy was prescribed for only one case
given ciproﬂoxacin 0.2 g. According to the guidelines; mono-
therapy was not indicated for treatment of CAP patients in
ICU. The greatest proportion of Group B patients (8 out of
9 patients) did not follow the ATS/IDSA guidelines. Antibiotic
monotherapy was prescribed for some patients such as(imipenem-cilastatin sodium 0.5 g monotherapy and ampicillin
1 g/sulbactam 0.5 g monotherapy).
All cases of Group A in the prospective study did not fol-
low the ATS/IDSA guidelines. Antibiotic monotherapy was
prescribed for some cases such as (ceftriaxone 1 g mono-
therapy, imipenem-cilastatin sodium 0.5 g monotherapy, levo-
ﬂoxacin 0.5 g monotherapy, piperacillin 4 g/tazobactam 0.5 g
monotherapy and ciproﬂoxacin 0.2 g monotherapy). All
patients’ antibiotic prescriptions in Group B did not follow
the guidelines as well. Antibiotic monotherapy was prescribed
for some cases such as (ceftriaxone 1 g monotherapy, cefepime
1 g monotherapy, imipenem-cilastatin sodium 0.5 g mono-
therapy and meropenem 0.5 g monotherapy).
3.4. Effectiveness parameters analysis
Long length of stay (LOS) in ICU, receipt of mechanical ven-
tilation, development of complications such as septic shock
and not improved SOFA scores on discharge are associated
with severity of community-acquired pneumonia and corre-
lated with mortality.
3.4.1. Retrospective results
There was statistically non-signiﬁcant difference at p-
value < 0.05 between both groups in the number of days in
ICU (p-value = 0.0580), in SOFA score on admission (p-
value = 0.1779) and in SOFA score on discharge (p-
value = 0.3881) (Fig. 1). One patient in (Group B) received
mechanical ventilation and died. In contrast, there were no
ventilated patients and no deaths in (Group A) (Table 3).
The difference was not statistically signiﬁcantly different.
3.4.2. Prospective results
The results in (Table 4) revealed that there was statistically
non-signiﬁcant difference between both groups in number of
days in ICU (p-value = 0.1712) and in SOFA score on dis-
charge (p-value = 0.2444), but there was signiﬁcant difference
in SOFA score on admission (p-value = 0.0193) (Fig. 2).
There was one patient who received mechanical ventilation
in Group A compared to 6 patients who were mechanically
ventilated in Group B. There was higher mortality in Group
Table 3 Medians of effectiveness parameters and factors associated with severity of community-acquired pneumonia for (Group A)
and (Group B) retrospective patients.
Parameter (Group A) (regimen containing
ﬂuoroquinolone) (n= 7)
(Group B) (regimen not containing
ﬂuoroquinolone) (n= 9)
P-value
Number of days in ICU 10 5 0.0580
SOFA scores on admission 4 2 0.1779
SOFA scores on discharge 2 1 0.3881
Number of patients who received mechanical ventilation 0 1 (11.1%) 1.0000
Number of deaths in ICU (arrest) 0 1 (11.1%) 1.0000
Other complications
Septic shock (need for vasopressor) 0 1 (11.1%)
Post arrest 0 1 (11.1%)
Level of signiﬁcance at p-value < 0.05 (Mann–Whitney test). Fisher’s exact test was done for data which presented as frequencies.
Table 4 Medians of effectiveness parameters and factors associated with severity of community-acquired pneumonia for (Group A)
and (Group B) prospective patients.
Parameter (Group A) (regimen containing
ﬂuoroquinolone) (n= 13)
(Group B) (regimen not containing
ﬂuoroquinolone) (n= 17)
P-value
Number of days in ICU 15 11 0.1712
SOFA scores on admission 3 2 0.0193*
SOFA scores on discharge 2 1 0.2444
Number of patients who received mechanical ventilation 1 (7.7%) 6 (35.3%) 0.1038
Number of deaths in ICU (arrest) 0 4 (23.5%) 0.1129
Other complications
Septic shock (need for vasopressor) 0 4 (23.5%)
Post arrest 0 4 (23.5%)
Level of signiﬁcance at p-value < 0.05 (Mann–Whitney test). Fisher’s exact test was done for data which presented as frequencies.
* Signiﬁcant difference.
Figure 2 The difference of medians of effectiveness parameters
between (Group A) and (Group B) prospective patients. Non-
signiﬁcant difference at p< 0.05 in number of days in ICU and
SOFA score on discharge; * signiﬁcant difference at p< 0.05 in
SOFA score on admission (Mann–Whitney test).
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was not statistically signiﬁcantly different.3.5. Cost calculation and analysis
ICU costs of feeding (food and ﬂuids) were reported by the
hospital to be 37.67 L.E/day while staff wages in the ICU were
2816.7 L.E/day. Because of costs of feeding and wages were
similar in all patients in both groups, ICU costs of feeding
and wages per hospital stay can be calculated dependent on
number of days in ICU for each patient.
Since comparison of effectiveness parameters between the
two groups in ICU showed no signiﬁcant differences, cost-min-
imization analysis (CMA) was chosen to analyze cost data
dependent on the equivalency of the two regimens containing
and not containing ﬂuoroquinolone. The data available for
the primary economic analysis (cost-minimization analysis)
in this study included all direct medical costs which were used
in the treatment of CAP patients in the ICU in addition to
number of days in ICU.
3.5.1. Retrospective results
There was no statistically signiﬁcant difference between the
two groups at p-value < 0.05 in the median total ICU costs
per hospital stay (p-value = 0.1413) and in medians of costs
of antibiotics (p-value = 0.2509), costs of medications other
than antibiotics (p-value = 0.2096), costs of feeding (p-
value = 0.0580) and costs of wages (staff) (p-value = 0.0580).
Table 5 The median total and treatment costs of CAP
patients in ICU for (Group A) and (Group B) retrospective
patients.
Cost parameter Group A Group B P-value
Total ICU costs per hospital stay 2688 1411 0.1413
Costs of antibiotics 1098 575.1 0.2509
Costs of medications other than
antibiotics
913.8 174.7 0.2096
Costs of Lab and diagnostic tests 616 426 0.0392*
Costs of feeding 376.7 188.4 0.0580
Costs of wages (staﬀ) 28,167 14,084 0.0580
Level of signiﬁcance at p-value < 0.05 (Mann–Whitney test).
Total ICU costs per hospital stay excluding costs of wages (staff)
and feeding.
* Signiﬁcant difference.
Figure 3 The difference of median total and treatment costs of
CAP patients in ICU between (Group A) and (Group B)
retrospective patients. Non-signiﬁcant difference at p< 0.05 in
the median of total ICU costs and median costs of antibiotics,
medications other than antibiotics, feeding and wages; * signiﬁcant
difference at p< 0.05 in median costs of Lab and diagnostic tests
(Mann–Whitney test).
Table 6 The median total and treatment costs of CAP
patients in ICU for (Group A) and (Group B) prospective
patients.
Cost parameter Group A Group B P-value
Total ICU costs per hospital stay 4408 3592 0.4535
Costs of antibiotics 2857 1980 0.3571
Costs of medications other than
antibiotics
573.5 431.1 0.8937
Costs of Lab and diagnostic tests 1067 866 0.6577
Costs of feeding 565.1 414.4 0.1712
Costs of wages (staﬀ) 42,251 30,984 0.1712
Level of signiﬁcance at p-value < 0.05; (Mann–Whitney test).
Total ICU costs per hospital stay excluding costs of wages (staff)
and feeding.
Figure 4 The difference of median total and treatment costs of
CAP patients in ICU between (Group A) and (Group B)
prospective patients. Non-signiﬁcant difference at p< 0.05
(Mann–Whitney test).
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two groups at (p-value < 0.05) in the median costs of labora-
tory and diagnostic tests (p-value = 0.0392) (Table 5) and
(Fig. 3).
3.5.2. Prospective results
Statistically non-signiﬁcant difference was obtained between
the two groups in the median total ICU costs per hospital stay
(p-value = 0.4535) and in medians of costs of antibiotics (p-
value = 0.3571), costs of medications other than antibiotics
(p-value = 0.8937), costs of laboratory and diagnostic tests
(p-value = 0.6577), costs of feeding (p-value = 0.1712) and
costs of wages (staff) (p-value = 0.1712) (Table 6) and (Fig. 4).
4. Discussion
In the current study, we compared antibiotic combination reg-
imen containing ﬂuoroquinolone (Group A) to antibiotic com-
bination regimen not containing ﬂuoroquinolone (Group B) in
terms of effectiveness parameters and cost analysis since this
has never been documented before in any Egyptian hospital.
The two groups were not statistically signiﬁcantly different in
efﬁcacy and direct medical costs associated with treatment of
CAP patients in ICU.
This study focused on ﬂuoroquinolones for the following
reasons: (1) ﬂuoroquinolones are included as an important
treatment option in the American Thoracic Society (ATS)
and the Infectious Diseases Society of America (IDSA) guide-
lines for treatment of CAP patients in ICU10,14; (2) they have a
number of advantageous pharmacokinetic properties, includ-
ing high penetration into the lung and high oral bioavailabil-
ity, and a good safety proﬁle.7 In addition to these
advantages of ﬂuoroquinolones, there was lower resistance
potential than other b-lactams and especially macrolides. For
this reason, the Centers for Disease Control and Prevention
recommend reserving ﬂuoroquinolones in CAP for patients
at risk for resistant pneumococcal infections.7,15 Fluoroquino-
lones (for example, levoﬂoxacin) have been also associated
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improvement of signs and symptoms and shorter hospital
length of stay compared to non-standardized treatment.8
Patients hospitalized with CAP especially those admitted to
the ICU with multidrug resistant (MDR) pathogens require
empiric intravenous broad-spectrum antibiotic therapy to pro-
vide appropriate initial atypical coverage.16 Empirical antibi-
otic therapy including macrolides (in combination with a
cephalosporin) or ﬂuoroquinolones (levoﬂoxacin) provide an
increased importance in reducing hospital length of stay
(LOS) and mortality.12,13,17 Respiratory ﬂuoroquinolones
(such as levoﬂoxacin) should be regarded as appropriate
ﬁrst-line antimicrobials for the monotherapeutic treatment of
CAP in outpatients and hospitalized patients, as well as in
combination with b-lactam antibiotics in those patients requir-
ing ICU admission. Respiratory ﬂuoroquinolones are consid-
ered the only antimicrobials that are highly active against S.
pneumoniae, including macrolide-resistant and penicillin-resis-
tant strains, H. inﬂuenzae, Legionella spp., and atypical
pathogens.7
It is clear that the hospital did not follow the ATS/IDSA
guidelines and this may be associated with negative impact
on length of stay in ICU, microbial resistance and costs of
hotel and antibiotics.
Effectiveness parameters and direct medical costs used to
compare treatments in both retrospective and prospective
phases of the study did not differ signiﬁcantly. The sample size
included in the two groups is too small to derive a statistically
signiﬁcant difference. This small number is due to the fact that
in one hospital the number of patients with severe CAP requir-
ing ICU admission is usually low. This was evident from the
retrospective screening study and in other international
studies.18
Data from the retrospective study showed that the median
number of days in ICU between both groups was non-signiﬁ-
cantly different with a 5-day reduction in the median length of
stay in the non-ﬂuoroquinolone group (Group B) compared to
the ﬂuoroquinolone group (Group A). In addition, there was
non-signiﬁcant difference between the two groups in SOFA
score on admission and on discharge indicating that the two
regimens compared in the two groups were clinically equally
efﬁcacious. Due to the small sample size, occurrence of
mechanical ventilation and death was not statistically compa-
rable and we could not judge if this difference is due to ﬂuor-
oquinolones or not. Total median ICU costs per hospital stay
between the two groups were statistically insigniﬁcantly differ-
ent as well with cost difference of (L.E) 1277 with a trend to
lower costs in the non-ﬂuoroquinolone group (Group B).
In the prospective study, the median number of days in
ICU did not differ signiﬁcantly between the two groups with
a 4-day reduction in the median length of stay in the non-ﬂuo-
roquinolone group (Group B). There was signiﬁcant difference
in SOFA score on admission but non-signiﬁcant difference in
SOFA score on discharge. However, the median scores for
both groups were 3 and 2 which are not clinically signiﬁcantly
different, since all patients in all groups did not exceed a score
of 9 on admission.11 Even though there was one patient who
received mechanical ventilation with no deaths in (Group A),
there were 6 patients who were mechanically ventilated with
4 deaths in (Group B). Total median ICU costs per hospital
stay between the two groups were statistically non-signiﬁcantlydifferent with cost difference of (L.E) 816 with a trend to lower
costs in the non-ﬂuoroquinolone group (Group B).
Overall there was no death in patients receiving levoﬂoxa-
cin and only one patient received mechanical ventilation but
due to the small sample number the difference was not found
to be statistically signiﬁcantly different.
The major ﬁndings of the present costs analysis are: (1) the
major contributors to the medical direct costs were treatment
costs, hotel and medical staff costs; (2) the major determinant
of direct medical costs included in the treatment of CAP hos-
pitalized patients was length of stay (LOS) in ICU. Hospital
(LOS) considered a signiﬁcant cost factor in treating CAP hos-
pitalized patients and may contribute to higher costs especially
in the ICU.19 Consistent with our analysis, Bauer et al.18 iden-
tiﬁed the length of stay and ICU admission as the two most
important single predictors of resource utilization in the treat-
ment of CAP hospitalized patients.
Average LOS of 12.59 days in the present study was longer
than average LOS of less than 1–5 days reported in the litera-
ture.8,18 The longer LOS may be attributed to the non-adher-
ence to the ATS/IDSA guidelines. If the hospital follows these
guidelines or its own guidelines, possibly there will be faster
improvement of signs and symptoms, lower microbial resis-
tance; consequently lower length of stay in ICU and lower
costs of hotel and antibiotics.
Comparing the results of the present study to the literature
showed that our results were in accordance with Samsa et al.13,
Bauer et al.18 and Drummond et al.8 who showed that there
was non-signiﬁcant difference in both efﬁcacy and direct med-
ical costs associated with treatment of hospitalized CAP
patients; while Dresser et al.12 and Torres et al.20 agreed with
our effectiveness parameter results and revealed that there was
non-signiﬁcant difference in the efﬁcacy between the two
groups.
Samsa et al.13 showed that there was a longer hospital stay
in levoﬂoxacin group patients compared to azithromycin
group patients who experienced a shorter hospitalization with
a 1.8-day reduction in the average length of stay than the lev-
oﬂoxacin group and revealed that there was non-signiﬁcant
difference in clinical success rates (i.e. similar clinical success
rates deﬁned as cured and improved). They also concluded
that there was a trend to lower direct medical costs associated
with the azithromycin group than the corresponding costs in
the levoﬂoxacin group and this non-signiﬁcant difference in
costs resulting from the 1.8-day reduction in the average length
of stay.
In addition, Bauer et al.18 concluded that there was a little
tendency to high clinical efﬁcacy with initial antibiotic therapy
with moxiﬂoxacin compared to non-standardized therapy but
did not differ signiﬁcantly. Also, there was non-signiﬁcant dif-
ference but a trend to lower direct medical costs in the moxi-
ﬂoxacin cohort compared to the non-standardized treatment
group. A trend to lower costs in the moxiﬂoxacin cohort
may be also because of the lower number of patients in addi-
tion to monotherapy treatment. They also reported that mor-
tality was signiﬁcantly higher in the non-standardized
antibiotics cohort compared to the moxiﬂoxacin cohort and
this higher mortality may be due to the fact that there were
more severe cases enrolled in the non-standardized antibiotics
cohort. However, mechanical ventilation and mortality could
not be statistically compared in the present study.
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ters (clinical cure rate) although in favor of moxiﬂoxacin were
not statistically signiﬁcantly different between both groups.
They also demonstrated that empirical treatment with sequen-
tial IV/oral moxiﬂoxacin monotherapy is less costly relative to
IV/oral co-amoxiclav with or without clarithromycin and the
treatment with moxiﬂoxacin is likely to result in cost savings
per additional patient cured to health care payers which is
mainly due to the shorter length of stay; but they showed that
cost savings associated with moxiﬂoxacin also did not reach
statistically signiﬁcance levels due to the higher variability of
cost data. Dresser et al.12 concluded that clinical outcomes
analysis in terms of (clinical cure rate, microbiological eradica-
tion rate and treatment failure) were not powered to demon-
strate a statistically signiﬁcant difference, but did show a
trend toward improved clinical outcomes with ﬂuoroquinolone
(gatiﬂoxacin) monotherapy. Torres et al.20 also concluded that
sequential intravenous and oral moxiﬂoxacin monotherapy
was non-inferior to a combination of intravenous ceftriaxone
plus sequential intravenous and oral levoﬂoxacin for the treat-
ment of hospitalized patients with CAP III–V. There was a
good correlation between clinical cure and bacteriological suc-
cess, and both regimens were safe and well tolerated.
On the other hand, Finch et al.21 and File et al.22 disagreed
with our effectiveness parameter results and showed that there
was signiﬁcant difference in the efﬁcacy between both groups;
while Dresser et al.12 disagreed with our cost analysis results
and concluded that there was signiﬁcant difference in the costs
between the two comparable groups.
Finch et al.21 concluded that monotherapy with moxiﬂoxa-
cin is superior (statistically signiﬁcant higher clinical success
rates, signiﬁcantly faster resolution of fever, lower duration
of hospital admission, fewer deaths and fewer serious adverse
events) to that with a standard combination regimen of a b-lac-
tam and a b-lactamase inhibitor, co-amoxiclav, with or with-
out a macrolide, clarithromycin, in the treatment of
hospitalized CAP patients. File et al.22 who compared IV
and/or oral levoﬂoxacin monotherapy versus IV ceftriaxone
and/or oral cefuroxime axetil with or without erythromycin
or doxycycline in hospitalized CAP patients also showed that
there was a statistically signiﬁcant difference in the clinical suc-
cess rate in favor of levoﬂoxacin. In addition, Dresser et al.12
cost analysis offers further evidence that ﬂuoroquinolone (gati-
ﬂoxacin) monotherapy is a cost-effective alternative with lower
medical costs including drug costs and non-drug costs over the
standard regimen of IV ceftriaxone with or without an IV
macrolide.5. Conclusion
In conclusion, despite the fact that there was non-signiﬁcant
difference in the number of days in ICU and the overall costs
between the two groups, there was a trend toward shorter
length of stay in ICU and lower medical costs in the non-ﬂuo-
roquinolone group in both retrospective and prospective stud-
ies. The length of stay in ICU in this Egyptian hospital for
CAP patients was on average longer than previous interna-
tional studies. The hospital did not adopt any antibiotic poli-
cies which could be partly the cause of the longer length of
stay. Further future multicenter clinical trials on a larger sam-
ple size are required to investigate the effectiveness and costsanalysis of antibiotics used for the treatment of CAP in the
ICU in Egypt. Proper antibiotic policies should be adopted
and implemented to be able to provide a higher level of
healthcare.
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